Misko Tessianna A, Wijerathna Sanath R, Radivoyevitch Tomas, Berdis Anthony J, Ahmad Md Faiz, Harris Michael E, Dealwis Chris G
Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
Department of Quantitative Health Sciences, Cleveland Clinic Foundation, OH, USA.
FEBS Lett. 2016 Jun;590(12):1704-12. doi: 10.1002/1873-3468.12207. Epub 2016 May 27.
Sml1 is an intrinsically disordered protein inhibitor of Saccharomyces cerevisiae ribonucleotide reductase (ScRR1), but its inhibition mechanism is poorly understood. RR reduces ribonucleoside diphosphates to their deoxy forms, and balances the nucleotide pool. Multiple turnover kinetics show that Sml1 inhibition of dGTP/ADP- and ATP/CDP-bound ScRR follows a mixed inhibition mechanism. However, Sml1 cooperatively binds to the ES complex in the dGTP/ADP form, whereas with ATP/CDP, Sml1 binds weakly and noncooperatively. Gel filtration and mutagenesis studies indicate that Sml1 does not alter the oligomerization equilibrium and the CXXC motif is not involved in the inhibition. The data suggest that Sml1 is an allosteric inhibitor.
Sml1是酿酒酵母核糖核苷酸还原酶(ScRR1)的一种内在无序蛋白抑制剂,但其抑制机制尚不清楚。核糖核苷酸还原酶将核糖核苷二磷酸还原为脱氧形式,并平衡核苷酸库。多周转动力学表明,Sml1对结合dGTP/ADP和ATP/CDP的ScRR的抑制遵循混合抑制机制。然而,Sml1以dGTP/ADP形式协同结合到ES复合物上,而对于ATP/CDP,Sml1结合较弱且无协同作用。凝胶过滤和诱变研究表明,Sml1不会改变寡聚化平衡,CXXC基序也不参与抑制作用。数据表明Sml1是一种别构抑制剂。